Search NIOSH | NIOSH Home | NIOSH Topics | Site Index | Databases and Information Resources | NIOSH Products | Contact Us |
Cancer, Reproductive, and Cardiovascular DiseasesOutcomesOutcomes are events, occurrences, or conditions that indicate progress in achieving the purpose of the program. Outcomes reflect the results of a program activity compared with its intended purpose, or outcomes may answer the question, "Will these resources result in success or contribute to the success of what we want to accomplish?" Outcomes can be viewed from two different perspectives—ultimate and intermediate. For an occupational safety and health research program like the NIOSH Cancer, Reproductive, and Cardiovascular Diseases Program, ultimate outcomes are reductions in a particular type of worker illness or adverse reproductive event. These health outcomes have complex causes, and any effect of program activities on rates can take years to be seen. Therefore, outcomes are often measured on an intermediate timeframe. Intermediate outcomes are necessary steps that lead to ultimate outcomes—for example, reductions in the risk of a particular type of injury or illness. For occupational safety and health research programs, achieving intermediate risk reductions is as important as achieving the ultimate outcome of decreasing injury and illness incidence rates. Intermediate OutcomesAlthough demonstrating ultimate outcomes for the CRC is difficult, provision of research findings that will be influential in the refinement of State, Federal, and international radiation exposure standards have resulted in intermediate outcomes that would be expected to contribute toward the desired end outcomes—reduced incidence of occupational cancer. These findings are transferred via peer-reviewed publications, direct communications with workers and worker representatives, and presentations (see above). Among the customers for CRC research are OSHA and IARC. OSHAOSHA is mandated to regulate occupational safety and health in the United States. OSHA does this in part by creating OSHA Standards, which are regulations addressing occupational safety and health set forth in title 29 of the Code of Federal Regulations (CFR)—these regulations may be substance specific or may cover a broader topic. Most of the studies that have gained prominence for NIOSH in occupational cancer epidemiology and have had significant regulatory impact were initiated prior to 1985 (uranium miners, beryllium, ethylene oxide, formaldehyde, and cadmium). OSHA has not frequently issued new substance-specific standards in the past 10 years—among the more recent OSHA standards is the OSHA Cadmium standard (29 CFR 1910.1027), the provisions of which became effective as of December 11, 1992. CRC data concerning cadmium as an occupational carcinogen were used by OSHA in the creation of the cadmium standard.1 Specifically, in the preamble to Final Rule for the OSHA Cadmium Standard, Section 5-V. Health Effects, Section 8, Studies of the U.S. Cadmium Smelter Cohort (Globe), OSHA reports in detail on NIOSH CRC data used to support the OSHA Standard.2, 3 The CRC data included estimates of cadmium exposures and an evaluation of the mortality experience of workers in the cohort by standardized mortality ratios per dose group. An excess of lung cancer mortality was observed in relation to cadmium exposure. International Agency for Research on Cancer (IARC)Another organization that has an impact on safety and health for workers around the world is IARC. IARC categorizes substances or exposure conditions relative to the available evidence concerning their potential carcinogenicity. Regarding this IARC categorization, CRC studies contributed to the categorization of 22 (63%) of the 35 industrial agents categorized by IARC as Group 1 (having sufficient evidence of carcinogenicity in humans) and to 15 (45%) of the 33 industrial and agricultural agents listed in IARC Group 2A (probably carcinogenic to humans).4 NIOSH has conducted studies on 17 industrial agents listed in IARC Group 2B. Among the more recent studies from CRC used by IARC, CRC data from studies on cadmium and beryllium have been used by IARC in the recommendations of working groups to move those substances from Group 2 to Group 1.5 CRC laboratory research on 4,4’ methylene bis-2-chloroaniline (MOCA) found binding of MOCA to hemoglobin and DNA in animals, with five different adducts found in rat liver. Two of the five adducts found were identified in HUC cells, a human urothelial cell line. Two of the five adducts were found in exfoliated cells from a worker. A CRC bladder cancer incidence study among workers exposed to MOCA found three workers with bladder cancer.6 Based in part on this CRC research, IARC changed its classification of MOCA to probable human carcinogen (Group 2a).7 Other Intermediate OutcomesA variety of other intermediate outcomes have resulted from CRC research. For example:
References
|
NIOSH Program Portfolio:Cancer, Reproductive, and Cardiovascular Diseases |
||||||